Conjugate serogroup C meningococcal vaccine use extended in the United Kingdom

The United Kingdom (UK) Joint Committee on Vaccination and Immunisation (JCVI) has reviewed the epidemiology of group C infection in the population aged 20 years and over and recommended that immunisation should be made available for individuals aged 20-24 years (born after 7 January 1977) (1). The vaccine has already been offered to people who are under 20 years of age (2). This decision comes following successful reduction in disease in the UK of children and young people offered the conjugate meningococcal C vaccine (Men C vaccine).